Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting
Circulation2017Vol. 135(22), pp. 2091–2101
Citations Over TimeTop 1% of 2017 papers
Pradeep Natarajan, Robin Young, Nathan O. Stitziel, Sandosh Padmanabhan, Usman Baber, Roxana Mehran, Samantha Sartori, Valentı́n Fuster, Dermot F. Reilly, Adam S. Butterworth, Daniel J. Rader, Ian Ford, Naveed Sattar, Sekar Kathiresan
Abstract
URL: http://www.clinicaltrials.gov. Unique identifiers: NCT00738725 (BioImage) and NCT00005130 (CARDIA). WOSCOPS was carried out and completed before the requirement for clinical trial registration.
Related Papers
- → Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease(2016)81 cited
- → Trends in Statin Use 2009–2015 in a Large Integrated Health System: Pre- and Post-2013 ACC/AHA Guideline on Treatment of Blood Cholesterol(2018)46 cited
- → Abstract 072: Statin Eligibility And Use For Primary Prevention Among US Adults Across Strata Of Atherosclerotic Cardiovascular Disease Risk(2022)1 cited
- → Clinical Implications of Genetic Profiling, Polygenic Risk Scores, LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease (ASCVD) – What is New?(2021)1 cited
- Abstract 15219: Statin Decision-Making Since the 2013 AHA/ACC Cholesterol Guidelines: Do Clinicians Do What They Say?(2017)